一种合理的腹水治疗方法。
A rational approach to the treatment of ascites.
作者信息
Arroyo V, Rodés J
出版信息
Postgrad Med J. 1975 Aug;51(598):558-62. doi: 10.1136/pgmj.51.598.558.
Abstract
A rational approach to the diuretic therapy of ascites is proposed. Fifty-five patients were classified according to their ability to excrete sodium and free water. Patients with a high urinary sodium excretion can be treated by low sodium intake alone. In most patients with a low sodium excretion but high free water clearance, distal diuretics (spironolactone or triamterene) with a low sodium diet will relieve ascites. Patients with low values for sodium excretion and free water clearance also have poor glomerular filtration rate and only a few of these will respond to diuretic therapy.
摘要
本文提出了一种治疗腹水的利尿疗法的合理方法。55例患者根据其排泄钠和自由水的能力进行分类。尿钠排泄高的患者仅通过低钠摄入即可治疗。大多数尿钠排泄低但自由水清除率高的患者，使用远端利尿剂（螺内酯或氨苯蝶啶）并采用低钠饮食可缓解腹水。钠排泄和自由水清除率低的患者肾小球滤过率也低，其中只有少数患者会对利尿疗法有反应。
相似文献
1
A rational approach to the treatment of ascites.一种合理的腹水治疗方法。
Postgrad Med J. 1975 Aug;51(598):558-62. doi: 10.1136/pgmj.51.598.558.
2
Physiologic considerations in the medical management of ascites.腹水医学管理中的生理学考量
Arch Intern Med. 1980 May;140(5):620-3.
3
Patient selection is important in studying the impact of large-volume paracentesis on intravascular volume.在研究大量腹腔穿刺放液对血管内容量的影响时，患者选择很重要。
Am J Gastroenterol. 1997 Mar;92(3):371-3.
4
[Clinical application of diuretics: ascites].[利尿剂的临床应用：腹水]
Nihon Rinsho. 1984 Sep;42(9):2051-6.
5
[Use of diuretics in the treatment of ascites in patients with cirrhosis].
Acta Gastroenterol Belg. 1990 Mar-Apr;53(2):256-60.
6
The impact of diuretics on chronic liver disease.利尿剂对慢性肝病的影响。
Am J Gastroenterol. 1969 Jul;52(1):37-44.
7
Prevention of diuretic-induced electrolyte disturbances by amiloride in patients with ascites due to cirrhosis of the liver.
Acta Cardiol. 1973:Suppl 17:307-1.
8
[Effect of amiloride (MK 870) on water and electrolyte metabolism in ascitic cirrhotics].[氨氯吡咪（MK 870）对腹水型肝硬化患者水和电解质代谢的影响]
Schweiz Med Wochenschr. 1969 Jan 4;99(1):21-6.
9
[THE TREATMENT OF DECOMPENSATING, ASCITES-FORMING LIVER CIRRHOSIS (WITH A SURVEY ON THE PATHOGENESIS OF ASCITES)].[失代偿性腹水型肝硬化的治疗（附腹水发病机制综述）]
Langenbecks Arch Klin Chir Ver Dtsch Z Chir. 1963 Oct 30;303:404-26.
10
[Treatment of ascites in cirrhosis of the liver].[肝硬化腹水的治疗]
Rev Med Chil. 1965 Sep;93(9):549-56.
引用本文的文献
1
Lipoprotein profile of pleural and peritoneal transudates in dogs and cats.犬猫胸腔和腹腔渗出液的脂蛋白谱。
J Vet Intern Med. 2022 Mar;36(2):464-472. doi: 10.1111/jvim.16369. Epub 2022 Feb 15.
2
Outcomes of transjugular intrahepatic portosystemic shunts for ascites.经颈静脉肝内门体分流术治疗腹水的疗效
Semin Intervent Radiol. 2014 Sep;31(3):248-51. doi: 10.1055/s-0034-1382792.
3
Evaluation and management of patients with refractory ascites.难治性腹水患者的评估与管理
World J Gastroenterol. 2009 Jan 7;15(1):67-80. doi: 10.3748/wjg.15.67.
4
Pharmacokinetics of furosemide in patients with hepatic cirrhosis.呋塞米在肝硬化患者中的药代动力学。
Eur J Clin Pharmacol. 1982;22(4):315-20. doi: 10.1007/BF00548399.
5
Treatment of ascites in patients with cirrhosis of the liver.
Intensive Care Med. 1987;13(3):154-61. doi: 10.1007/BF00254698.
6
Coagulopathy post peritoneovenous shunt.腹膜静脉分流术后凝血病
Ann Surg. 1987 Mar;205(3):305-11. doi: 10.1097/00000658-198703000-00015.
7
Traditional management of liver disorders.肝脏疾病的传统管理方法。
Drugs. 1990;40 Suppl 3:45-57. doi: 10.2165/00003495-199000403-00005.
8
Pharmacotherapy of ascites associated with cirrhosis.肝硬化相关腹水的药物治疗。
Drugs. 1992 Mar;43(3):316-32. doi: 10.2165/00003495-199243030-00003.
本文引用的文献
1
Plasma volume in cirrhosis of the liver: its relation of portal hypertension, ascites, and renal failure.肝硬化患者的血浆容量：其与门脉高压、腹水和肾衰竭的关系。
J Clin Invest. 1967 Aug;46(8):1297-308. doi: 10.1172/JCI105622.
2
Rôle of sodium in the formation and control of ascites in patients with cirrhosis.钠在肝硬化患者腹水形成及控制中的作用。
Ann Intern Med. 1952 Aug;37(2):261-72. doi: 10.7326/0003-4819-37-2-261.
3
Hyponatremia in hepatic cirrhosis following paracentesis.肝硬化患者腹腔穿刺术后低钠血症
J Clin Invest. 1951 Jul;30(7):738-44. doi: 10.1172/JCI102487.
4
Renal failure in Laennec's cirrhosis of the liver. I. Description of clinical and laboratory features.Laennec肝硬化中的肾衰竭。I. 临床和实验室特征描述。
Ann Intern Med. 1959 Oct;51:759-73. doi: 10.7326/0003-4819-51-4-759.
5
RENAL FAILURE IN PATIENTS WITH CIRRHOSIS OF THE LIVER. II. FACTORS INFLUENCING MAXIMAL URINARY FLOW RATE.肝硬化患者的肾衰竭。II. 影响最大尿流率的因素。
Am J Med. 1965 Aug;39:199-209. doi: 10.1016/0002-9343(65)90042-2.
6
7
THE KIDNEY IN CIRRHOSIS. II. DISORDERS OF RENAL FUNCTION.肝硬化中的肾脏。II. 肾功能紊乱。
Ann Intern Med. 1964 Mar;60:366-77. doi: 10.7326/0003-4819-60-3-366.
8
Plasma colloid osmotic pressure in relation to the formation of ascites and oedema in liver disease.
Clin Sci. 1962 Jun;22:383-9.
9
The role of the kidney in Laennec's cirrhosis of the liver.肾脏在Laennec肝硬化中的作用。
Medicine (Baltimore). 1958 Dec;37(4):299-316. doi: 10.1097/00005792-195812000-00002.
10
Electrolyte and circulatory changes in terminal liver failure.终末期肝功能衰竭时的电解质及循环系统变化
Lancet. 1956 Dec 1;271(6953):1121-5. doi: 10.1016/s0140-6736(56)90149-0.
Zotero 插件